LV10044B - Transdermal composition - Google Patents

Transdermal composition Download PDF

Info

Publication number: LV10044B
Authority: LV; Latvia
Prior art keywords: weight; methyl; propyl; propynylamine; transdermal
Prior art date: 1991-04-15

Application number

LVP-92-07A

Other languages

English (en)

Latvian (lv)

Other versions

LV10044A (lv

Inventor

Anna Z Szabo

Gabriella Szabo-Nee-Ujhelyi

Antal Toth

Tamas Sz Ts

Kalman Dr Magyar

Jozsef Lengyel

Janos Pinter

Anna Szekely

Andras Szeg

Katalin Marmarosi-Nee-Kellner

Original Assignee

Chinoin Gyogyszer Es Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-15

Filing date

1992-04-09

Publication date

1995-02-20

1992-04-09 Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet

1994-05-10 Publication of LV10044A publication Critical patent/LV10044A/xx

1995-02-20 Publication of LV10044B publication Critical patent/LV10044B/en

Links

239000000203 mixture Substances 0.000 title claims description 24
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 30
239000007788 liquid Substances 0.000 claims abstract description 25
238000002360 preparation method Methods 0.000 claims abstract description 19
229920000642 polymer Polymers 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 9
239000007787 solid Substances 0.000 claims abstract description 9
MEZLKOACVSPNER-UHFFFAOYSA-N selegiline Chemical compound C#CCN(C)C(C)CC1=CC=CC=C1 MEZLKOACVSPNER-UHFFFAOYSA-N 0.000 claims abstract 4
MUDUXRHPVDVWHU-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-methyl-n-prop-2-ynylpropan-2-amine Chemical compound C#CCN(C)C(C)CC1=CC=C(F)C=C1 MUDUXRHPVDVWHU-UHFFFAOYSA-N 0.000 claims abstract 3
239000004094 surface-active agent Substances 0.000 claims abstract 2
239000004480 active ingredient Substances 0.000 claims description 22
238000000034 method Methods 0.000 claims description 9
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
239000004973 liquid crystal related substance Substances 0.000 claims description 2
-1 polyoxyethylene Polymers 0.000 claims 4
239000004976 Lyotropic liquid crystal Substances 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
239000003995 emulsifying agent Substances 0.000 claims 1
239000002736 nonionic surfactant Substances 0.000 claims 1
229960004063 propylene glycol Drugs 0.000 abstract description 9
235000013772 propylene glycol Nutrition 0.000 abstract description 9
230000002535 lyotropic effect Effects 0.000 abstract description 8
239000012752 auxiliary agent Substances 0.000 abstract 1
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 25
102000010909 Monoamine Oxidase Human genes 0.000 description 19
108010062431 Monoamine oxidase Proteins 0.000 description 19
230000000694 effects Effects 0.000 description 17
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 10
241000700159 Rattus Species 0.000 description 7
241000282887 Suidae Species 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
229960003946 selegiline Drugs 0.000 description 7
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000002245 particle Substances 0.000 description 6
239000011505 plaster Substances 0.000 description 6
208000018737 Parkinson disease Diseases 0.000 description 5
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 5
239000008389 polyethoxylated castor oil Substances 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
210000001772 blood platelet Anatomy 0.000 description 4
230000001804 emulsifying effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000002674 ointment Substances 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000002500 effect on skin Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000005228 liver tissue Anatomy 0.000 description 3
239000000758 substrate Substances 0.000 description 3
229920001285 xanthan gum Polymers 0.000 description 3
239000000230 xanthan gum Substances 0.000 description 3
229940082509 xanthan gum Drugs 0.000 description 3
235000010493 xanthan gum Nutrition 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 2
238000010241 blood sampling Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
241000772991 Aira Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 description 1
229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
239000011149 active material Substances 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019994 cava Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000002825 dopamine reuptake Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000003557 neuropsychological effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229940066675 ricinoleate Drugs 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dispersion Chemistry (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LVP-92-07A 1991-04-15 1992-04-09 Transdermal composition LV10044B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU911229A HU209605B (en)	1991-04-15	1991-04-15	Process for production of wather-free transdermal preparation

Publications (2)

Publication Number	Publication Date
LV10044A LV10044A (lv)	1994-05-10
LV10044B true LV10044B (en)	1995-02-20

Family

ID=10953442

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-92-07A LV10044B (en)	1991-04-15	1992-04-09	Transdermal composition

Country Status (35)

Country	Link
US (1)	US5380761A (cs)
EP (1)	EP0509761B1 (cs)
JP (1)	JP2547151B2 (cs)
KR (1)	KR950008766B1 (cs)
AT (1)	ATE142486T1 (cs)
AU (1)	AU648886B2 (cs)
BG (1)	BG61637B1 (cs)
CA (1)	CA2065134A1 (cs)
CZ (1)	CZ281261B6 (cs)
DE (1)	DE69213536T2 (cs)
DK (1)	DK0509761T3 (cs)
EC (1)	ECSP920873A (cs)
EE (1)	EE03038B1 (cs)
ES (1)	ES2092031T3 (cs)
FI (1)	FI101677B (cs)
GR (1)	GR3021505T3 (cs)
HK (1)	HK1003977A1 (cs)
HR (1)	HRP920570A2 (cs)
HU (2)	HU209605B (cs)
IE (1)	IE921019A1 (cs)
IL (1)	IL101487A (cs)
LT (1)	LT3044B (cs)
LV (1)	LV10044B (cs)
MX (1)	MX9201732A (cs)
NO (1)	NO303903B1 (cs)
NZ (1)	NZ242335A (cs)
PH (1)	PH29992A (cs)
PL (1)	PL173234B1 (cs)
RO (1)	RO109603B1 (cs)
RU (1)	RU2088617C1 (cs)
SK (1)	SK278666B6 (cs)
TW (1)	TW198690B (cs)
UA (1)	UA26892C2 (cs)
YU (1)	YU48552B (cs)
ZA (1)	ZA922355B (cs)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6313176B1 (en)	1989-10-17	2001-11-06	Everett J. Ellinwood, Jr.	Dosing method of administering deprenyl via intraoral administration or inhalation administration
HUT63579A (en) *	1991-12-20	1993-09-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
AU679937B2 (en) *	1992-11-18	1997-07-17	Johnson & Johnson Consumer Products, Inc.	Extrudable compositions for topical or transdermal drug delivery
US5817336A (en) *	1993-04-02	1998-10-06	Orion-Yhtyma Oy	Composition containing selegiline
DE4428444A1 (de) *	1994-08-11	1996-02-15	Dresden Arzneimittel	Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen
HU223475B1 (hu) *	1994-10-24	2004-07-28	Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt.	Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US6348208B1 (en) *	1995-01-13	2002-02-19	Somerset Pharmaceuticals, Inc.	Methods and pharmaceutical compositions employing desmethylselegiline
US6033682A (en)	1995-01-13	2000-03-07	Somerset Pharmaceuticals, Inc.	S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6319954B1 (en)	1995-01-13	2001-11-20	Somerset Pharmaceuticals, Inc.	S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en)	1995-01-13	2001-10-09	Somerset Pharmaceuticals, Inc.	Methods and pharmaceutical compositions employing desmethylselegiline
CA2223588C (en)	1995-06-07	2004-01-06	Noven Pharmaceuticals, Inc.	Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en)	1995-06-07	2001-11-13	Noven Pharmaceuticals, Inc.	Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
HUP9601442A3 (en) *	1995-07-25	1999-03-29	Panacea Biotec Ltd	Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
JP2002513383A (ja)	1997-05-21	2002-05-08	スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ	患者の脳組織でのアスコルビン酸の濃度を増加させる方法
US6262111B1 (en)	1997-05-21	2001-07-17	Sloan-Kettering Institute For Cancer Research	Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US7150881B2 (en)	1997-06-26	2006-12-19	Mylan Technologies, Inc.	Adhesive mixture for transdermal delivery of highly plasticizing drugs
DE19743323C2 (de) *	1997-09-30	2000-05-25	Iip Inst Fuer Ind Pharmazie Fo	Feste Arzneimittelzusammensetzung auf der Grundlage von Selegilin
DK1063981T3 (da)	1998-03-16	2002-10-14	Somerset Pharmaceuticals Inc	Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
DE19814257A1 (de) *	1998-03-31	1999-10-07	Asta Medica Ag	Brauseformulierungen
DE19922662C1 (de) *	1999-05-18	2000-12-28	Sanol Arznei Schwarz Gmbh	Transdermales therapeutisches System (TTS) Tolterodin enthaltend
US6316469B1 (en)	2000-03-01	2001-11-13	Duke University	Use of selective serotonin reuptake inhibitors for treatment of chest pain of non-cardiac origin and gastro-esophageal reflux disease
US8512718B2 (en)	2000-07-03	2013-08-20	Foamix Ltd.	Pharmaceutical composition for topical application
DE60231896D1 (de)	2001-11-05	2009-05-20	Krele Pharmaceuticals Llc	Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
US8435942B2 (en) *	2002-05-31	2013-05-07	Transdermal Biotechnology, Inc.	Methods for formulating stabilized insulin compositions
US20040018237A1 (en)	2002-05-31	2004-01-29	Perricone Nicholas V.	Topical drug delivery using phosphatidylcholine
IL152486A0 (en)	2002-10-25	2003-05-29	Meir Eini	Alcohol-free cosmetic and pharmaceutical foam carrier
US20080206161A1 (en) *	2002-10-25	2008-08-28	Dov Tamarkin	Quiescent foamable compositions, steroids, kits and uses thereof
US8900554B2 (en)	2002-10-25	2014-12-02	Foamix Pharmaceuticals Ltd.	Foamable composition and uses thereof
US8486376B2 (en) *	2002-10-25	2013-07-16	Foamix Ltd.	Moisturizing foam containing lanolin
US7820145B2 (en) *	2003-08-04	2010-10-26	Foamix Ltd.	Oleaginous pharmaceutical and cosmetic foam
US9265725B2 (en) *	2002-10-25	2016-02-23	Foamix Pharmaceuticals Ltd.	Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) *	2002-10-25	2018-11-06	Foamix Pharmaceuticals Ltd.	Foamable composition combining a polar solvent and a hydrophobic carrier
US20070292355A1 (en) *	2002-10-25	2007-12-20	Foamix Ltd.	Anti-infection augmentation foamable compositions and kit and uses thereof
US8119150B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Non-flammable insecticide composition and uses thereof
US9211259B2 (en)	2002-11-29	2015-12-15	Foamix Pharmaceuticals Ltd.	Antibiotic kit and composition and uses thereof
US8119109B2 (en) *	2002-10-25	2012-02-21	Foamix Ltd.	Foamable compositions, kits and methods for hyperhidrosis
US20080317679A1 (en) *	2002-10-25	2008-12-25	Foamix Ltd.	Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
ES2532906T5 (es) *	2002-10-25	2022-03-23	Foamix Pharmaceuticals Ltd	Espuma cosmética y farmacéutica
US20060018937A1 (en) *	2002-10-25	2006-01-26	Foamix Ltd.	Steroid kit and foamable composition and uses thereof
US20080138296A1 (en)	2002-10-25	2008-06-12	Foamix Ltd.	Foam prepared from nanoemulsions and uses
US20070292359A1 (en) *	2002-10-25	2007-12-20	Foamix Ltd.	Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20050186142A1 (en) *	2002-10-25	2005-08-25	Foamix Ltd.	Kit and composition of imidazole with enhanced bioavailability
US7704518B2 (en)	2003-08-04	2010-04-27	Foamix, Ltd.	Foamable vehicle and pharmaceutical compositions thereof
US20060193789A1 (en) *	2002-10-25	2006-08-31	Foamix Ltd.	Film forming foamable composition
US7700076B2 (en) *	2002-10-25	2010-04-20	Foamix, Ltd.	Penetrating pharmaceutical foam
US9668972B2 (en)	2002-10-25	2017-06-06	Foamix Pharmaceuticals Ltd.	Nonsteroidal immunomodulating kit and composition and uses thereof
US20050271596A1 (en) *	2002-10-25	2005-12-08	Foamix Ltd.	Vasoactive kit and composition and uses thereof
US20050205086A1 (en) *	2002-10-25	2005-09-22	Foamix Ltd.	Retinoid immunomodulating kit and composition and uses thereof
RU2326893C2 (ru) *	2003-04-16	2008-06-20	Кориум Интернэшнл	Ковалентное и нековалентное сшивание гидрофильных полимеров и адгезивные композиции, полученные с ними
US7575739B2 (en)	2003-04-28	2009-08-18	Foamix Ltd.	Foamable iodine composition
US8795693B2 (en)	2003-08-04	2014-08-05	Foamix Ltd.	Compositions with modulating agents
US8486374B2 (en) *	2003-08-04	2013-07-16	Foamix Ltd.	Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
HUP0303313A2 (hu) *	2003-10-09	2005-07-28	Richter Gedeon Vegyészeti Gyár Rt.	Transzdermális gyógyszerkészítmények
RU2283637C1 (ru) *	2005-03-22	2006-09-20	Общество с ограниченной ответственностью "Производственно-коммерческая фирма "Две линии"	Пластырь
WO2006118245A1 (ja) *	2005-04-28	2006-11-09	Japan Science And Technology Agency	皮膚再生促進剤
WO2007039825A2 (en) *	2005-05-09	2007-04-12	Foamix Ltd.	Saccharide foamable compositions
US20080152596A1 (en) *	2005-07-19	2008-06-26	Foamix Ltd.	Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20080166303A1 (en) *	2006-09-08	2008-07-10	Dov Tamarkin	Colored or colorable foamable composition and foam
WO2009007785A2 (en) *	2006-11-14	2009-01-15	Foamix Ltd.	Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20080260655A1 (en) *	2006-11-14	2008-10-23	Dov Tamarkin	Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
DE102007014286A1 (de) *	2007-03-19	2008-09-25	Universität Tübingen	Fluorsubstituierte Amphetamine und Amphetaminderivate und deren Verwendung
US8636982B2 (en)	2007-08-07	2014-01-28	Foamix Ltd.	Wax foamable vehicle and pharmaceutical compositions thereof
US20090130029A1 (en) *	2007-11-21	2009-05-21	Foamix Ltd.	Glycerol ethers vehicle and pharmaceutical compositions thereof
US9439857B2 (en)	2007-11-30	2016-09-13	Foamix Pharmaceuticals Ltd.	Foam containing benzoyl peroxide
US8518376B2 (en)	2007-12-07	2013-08-27	Foamix Ltd.	Oil-based foamable carriers and formulations
WO2009072007A2 (en)	2007-12-07	2009-06-11	Foamix Ltd.	Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
EP2242476A2 (en) *	2008-01-14	2010-10-27	Foamix Ltd.	Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2010125470A2 (en)	2009-04-28	2010-11-04	Foamix Ltd.	Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en)	2009-07-29	2011-02-03	Foamix Ltd.	Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en)	2009-07-29	2011-02-03	Foamix Ltd.	Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011064631A1 (en)	2009-10-02	2011-06-03	Foamix Ltd.	Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en)	2009-10-02	2017-12-26	Foamix Pharmaceuticals Ltd.	Methods for accelerated return of skin integrity and for the treatment of impetigo
JP5619438B2 (ja) *	2010-03-12	2014-11-05	株式会社フジモト・コーポレーション	セレギリン含有貼付製剤
CN103547258B (zh)	2011-03-17	2017-10-20	特兰斯德梅尔生物工艺股份有限公司	局部一氧化氮系统及其使用方法
US8871260B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Methods and compositions for muscular and neuromuscular diseases
US8871256B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871261B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Cancer treatments and compositions for use thereof
US8871254B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871259B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Techniques and systems for treatment of neuropathic pain and other indications
US8871257B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871258B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Treatment and prevention of learning and memory disorders
US8871262B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Treatment of skin and soft tissue infection with nitric oxide
US9849160B2 (en)	2013-03-13	2017-12-26	Transdermal Biotechnology, Inc.	Methods and systems for treating or preventing cancer
US9393265B2 (en)	2013-03-13	2016-07-19	Transdermal Biotechnology, Inc.	Wound healing using topical systems and methods
US9314422B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Peptide systems and methods for metabolic conditions
US9320706B2 (en)	2013-03-13	2016-04-26	Transdermal Biotechnology, Inc.	Immune modulation using peptides and other compositions
US9295637B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Compositions and methods for affecting mood states
US9750787B2 (en)	2013-03-13	2017-09-05	Transdermal Biotechnology, Inc.	Memory or learning improvement using peptide and other compositions
US9687520B2 (en)	2013-03-13	2017-06-27	Transdermal Biotechnology, Inc.	Memory or learning improvement using peptide and other compositions
US9241899B2 (en)	2013-03-13	2016-01-26	Transdermal Biotechnology, Inc.	Topical systems and methods for treating sexual dysfunction
US20140271731A1 (en)	2013-03-13	2014-09-18	Transdermal Biotechnology, Inc.	Cardiovascular disease treatment and prevention
US9314417B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Treatment of skin, including aging skin, to improve appearance
US9724419B2 (en)	2013-03-13	2017-08-08	Transdermal Biotechnology, Inc.	Peptide systems and methods for metabolic conditions
US9295647B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Systems and methods for delivery of peptides
US9393264B2 (en)	2013-03-13	2016-07-19	Transdermal Biotechnology, Inc.	Immune modulation using peptides and other compositions
US9314423B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Hair treatment systems and methods using peptides and other compositions
US9295636B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Wound healing using topical systems and methods
US20140271937A1 (en)	2013-03-13	2014-09-18	Transdermal Biotechnology, Inc.	Brain and neural treatments comprising peptides and other compositions
US20140271938A1 (en)	2013-03-13	2014-09-18	Transdermal Biotechnology, Inc.	Systems and methods for delivery of peptides
US9320758B2 (en)	2013-03-13	2016-04-26	Transdermal Biotechnology, Inc.	Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en)	2013-03-13	2016-05-17	Transdermal Biotechnology, Inc.	Cardiovascular disease treatment and prevention
US9314433B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Methods and systems for treating or preventing cancer
US9387159B2 (en)	2013-03-13	2016-07-12	Transdermal Biotechnology, Inc.	Treatment of skin, including aging skin, to improve appearance
SMT202100418T1 (it)	2015-03-02	2021-11-12	Medlab Clinical U S Inc	Sistemi di erogazione transmucosali e transdermici
US12168070B2 (en)	2015-03-02	2024-12-17	Medlab Clinical U.S., Inc.	Transmucosal and transdermal delivery systems
US10398641B2 (en)	2016-09-08	2019-09-03	Foamix Pharmaceuticals Ltd.	Compositions and methods for treating rosacea and acne

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US468218A (en)		1892-02-02		Door-securer
HU187775B (en) *	1982-07-14	1986-02-28	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu	New process for producing propargile-amines of pharmaceutical activity
US4868218A (en) *	1987-08-18	1989-09-19	Buyske Donald A	Method of treating depression
US4861800A (en)	1987-08-18	1989-08-29	Buyske Donald A	Method for administering the drug deprenyl so as to minimize the danger of side effects
IL88099A (en) *	1987-11-06	1992-02-16	Chinoin Gyogyszer Es Vegyeszet	Lyotropic liquid crystalline compositions
GB8807504D0 (en) *	1988-03-29	1988-05-05	Sandoz Ltd	Improvements in/relating to organic compounds
WO1990001298A1 (en)	1988-07-29	1990-02-22	Michelson Gary K	Improved spinal retractor
US5053227A (en) *	1989-03-22	1991-10-01	Cygnus Therapeutic Systems	Skin permeation enhancer compositions, and methods and transdermal systems associated therewith

1991
- 1991-04-15 HU HU911229A patent/HU209605B/hu not_active IP Right Cessation
1992
- 1992-03-30 IE IE101992A patent/IE921019A1/en not_active Application Discontinuation
- 1992-03-31 ZA ZA922355A patent/ZA922355B/xx unknown
- 1992-04-03 CA CA002065134A patent/CA2065134A1/en not_active Abandoned
- 1992-04-03 IL IL10148792A patent/IL101487A/en not_active IP Right Cessation
- 1992-04-07 PH PH44168A patent/PH29992A/en unknown
- 1992-04-08 RO RO92-200487A patent/RO109603B1/ro unknown
- 1992-04-09 LV LVP-92-07A patent/LV10044B/en unknown
- 1992-04-13 NZ NZ242335A patent/NZ242335A/en unknown
- 1992-04-13 CZ CS921110A patent/CZ281261B6/cs unknown
- 1992-04-13 SK SK1110-92A patent/SK278666B6/sk unknown
- 1992-04-13 KR KR1019920006147A patent/KR950008766B1/ko not_active Expired - Fee Related
- 1992-04-14 NO NO921481A patent/NO303903B1/no unknown
- 1992-04-14 BG BG96232A patent/BG61637B1/bg unknown
- 1992-04-14 MX MX9201732A patent/MX9201732A/es unknown
- 1992-04-14 AU AU14849/92A patent/AU648886B2/en not_active Ceased
- 1992-04-14 AT AT92303341T patent/ATE142486T1/de active
- 1992-04-14 EP EP92303341A patent/EP0509761B1/en not_active Expired - Lifetime
- 1992-04-14 DE DE69213536T patent/DE69213536T2/de not_active Expired - Fee Related
- 1992-04-14 DK DK92303341.9T patent/DK0509761T3/da active
- 1992-04-14 YU YU38492A patent/YU48552B/sh unknown
- 1992-04-14 ES ES92303341T patent/ES2092031T3/es not_active Expired - Lifetime
- 1992-04-14 RU SU925011496A patent/RU2088617C1/ru active
- 1992-04-15 JP JP4095681A patent/JP2547151B2/ja not_active Expired - Lifetime
- 1992-04-15 PL PL92294240A patent/PL173234B1/pl unknown
- 1992-04-15 FI FI921690A patent/FI101677B/fi active
- 1992-04-23 TW TW081103203A patent/TW198690B/zh active
- 1992-08-28 LT LTIP176A patent/LT3044B/lt not_active IP Right Cessation
- 1992-09-28 HR HR920570A patent/HRP920570A2/hr not_active Application Discontinuation
- 1992-10-15 EC EC1992000873A patent/ECSP920873A/es unknown
1993
- 1993-06-14 UA UA93002168A patent/UA26892C2/uk unknown
- 1993-10-20 US US08/140,279 patent/US5380761A/en not_active Expired - Fee Related
1994
- 1994-08-10 EE EE9400116A patent/EE03038B1/xx unknown
1995
- 1995-06-16 HU HU95P/P00215P patent/HU211544A9/hu unknown
1996
- 1996-10-30 GR GR960402874T patent/GR3021505T3/el unknown
1998
- 1998-04-16 HK HK98103149A patent/HK1003977A1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2092031T3 (es)	1996-11-16
CZ281261B6 (cs)	1996-07-17
EP0509761B1 (en)	1996-09-11
NO921481L (no)	1992-10-16
BG61637B1 (bg)	1998-02-27
LTIP176A (lt)	1994-03-25
AU648886B2 (en)	1994-05-05
TW198690B (cs)	1993-01-21
KR920019341A (ko)	1992-11-19
YU38492A (sh)	1995-03-27
PL173234B1 (pl)	1998-02-27
DK0509761T3 (cs)	1997-02-17
BG96232A (bg)	1993-12-24
LT3044B (en)	1994-09-25
RO109603B1 (ro)	1995-04-28
YU48552B (sh)	1998-11-05
AU1484992A (en)	1992-10-22
HRP920570A2 (en)	1994-08-31
FI921690A0 (fi)	1992-04-15
FI101677B1 (fi)	1998-08-14
IE921019A1 (en)	1992-10-21
NO921481D0 (no)	1992-04-14
EP0509761A1 (en)	1992-10-21
IL101487A (en)	1996-01-19
UA26892C2 (uk)	1999-12-29
SK278666B6 (en)	1997-12-10
EE03038B1 (et)	1997-10-15
GR3021505T3 (en)	1997-01-31
NZ242335A (en)	1994-06-27
LV10044A (lv)	1994-05-10
ATE142486T1 (de)	1996-09-15
PH29992A (en)	1996-10-29
CA2065134A1 (en)	1992-10-16
HUT63560A (en)	1993-09-28
FI921690L (fi)	1992-10-16
US5380761A (en)	1995-01-10
DE69213536T2 (de)	1997-03-20
MX9201732A (es)	1992-10-01
CS111092A3 (en)	1992-11-18
IL101487A0 (en)	1992-12-30
FI101677B (fi)	1998-08-14
ECSP920873A (es)	1994-02-02
ZA922355B (en)	1992-12-30
DE69213536D1 (de)	1996-10-17
HU911229D0 (en)	1991-10-28
JP2547151B2 (ja)	1996-10-23
KR950008766B1 (ko)	1995-08-08
RU2088617C1 (ru)	1997-08-27
HU209605B (en)	1994-09-28
HK1003977A1 (en)	1998-11-13
JPH06128152A (ja)	1994-05-10
PL294240A1 (en)	1993-09-20
NO303903B1 (no)	1998-09-21
HU211544A9 (en)	1995-12-28

Publication	Publication Date	Title
LV10044B (en)	1995-02-20	Transdermal composition
HK1003977B (en)	1998-11-13	Transdermal composition containing selegiline
EP0055029B1 (en)	1985-11-21	Preparations for the treatment of dermatoses
FR2619567A1 (fr)	1989-02-24	Cristaux de serum-albumine humaine et procede pour leur preparation
JPS62164632A (ja)	1987-07-21	安定化されたヒト組織プラスミノゲン活性化因子組成物
EP0617960B1 (en)	1996-10-16	Use of pyridoxal derivatives for the manufacture of a medicament for the treatment of cataract
CN104529945A (zh)	2015-04-22	使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
JPH10507162A (ja)	1998-07-14	７−ハロ−１，２，３，４−テトラヒドロ−３−アリール−６−キナゾリンスルホンアミドを含有する非経口溶液
JPS62145019A (ja)	1987-06-29	抗炎症剤
FR2460669A1 (fr)	1981-01-30	Compositions pharmaceutiques a base de rifamycine sv et ses sels adaptes au traitement du rhumatisme articulaire et procede pour leur preparation
JP3457687B2 (ja)	2003-10-20	白内障治療用薬剤
JP2015028043A (ja)	2015-02-12	Ｓ−アデノシルメチオニンの安定な塩およびその調製のための方法
CN111148526B (zh)	2023-03-10	一种kor受体激动剂药物组合物
JPS60120995A (ja)	1985-06-28	新規アミノ酸誘導体の製法
US4822817A (en)	1989-04-18	Remedy for bone disease
JPH0640914A (ja)	1994-02-15	フィソスチグミンの新誘導体、それらの用途及びそれらを含む製薬組成物
JPH0611704B2 (ja)	1994-02-16	角膜疾患治療用点眼剤
CZ299423B6 (cs)	2008-07-23	Nové BPC peptidové sole s organo-protektivní aktivitou, proces jejich prípravy a jejich použití v lécbe
EP3842032A1 (en)	2021-06-30	A pharmaceutical formulation
JP2002097137A (ja)	2002-04-02	パーキンソン病の予防および／または治療剤
JPH10512296A (ja)	1998-11-24	血小板凝集阻害剤を含有する医薬組成物
JPH02256610A (ja)	1990-10-17	ポリアロマティック化合物を含有する医薬用組成物